Clinical trial
Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in…
NCT00243542 · Allergan, Industry · Completed
Key facts
| NCT number | NCT00243542 |
|---|---|
| Title | Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency |
| Official title | ACZ ACN 01. A Phase 4, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Cross-Over Study to Further Evaluate the Risk of Hematological Adverse Events in G6PD-Deficient Subjects With Acne Vulgaris Treated With ACZONE™ (Dapsone) Gel, 5%. |
| Lead sponsor | Allergan, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Acne Vulgaris |
| Intervention type | Drug |
| Interventions | ACZONE Gel, 5%, Vehicle |
| Enrollment | 64 |
| Start date | Nov 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Oct 24, 2005 |
| Last update posted | May 30, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: